Lindahl acted as legal advisor to Corline Biomedical

Through the agreement, Imperative Care is given the exclusive right to use CHS™ in all types of neurovascular products given a certain level of compensation. Corline undertakes to supply CHS™-coated products according to defined specifications, but also to assist in further development and market registration of the current product. In addition, Corline will participate in the development of additional CHS™-coated products within the indication area. These products have the potential to generate revenue for Corline of approximately SEK 150 million per year and a total of more than SEK 1 billion.
Lindahl's team consisted of Hugo Norlén and Erika Svensson.
Corline's press release (in Swedish) is available here.
Do you want to know more? Contact:
Hugo Norlén
Partner | AdvokatErika Svensson
Partner | AdvokatCarousel items
-
News articles
4/7/2025
Axel Hedberg appointed new CIO at Lindahl
Advokatfirman Lindahl is advancing its development and digitalisation journey by merging IT and Knowledge Management. The newly formed department will be led by Axel Hedberg, who has been appointed as CIO.
-
Cases and transactions
4/7/2025
Lindahl advisors to Amplex in two acquisitions
Lindahl has acted as legal advisor to Amplex in connection with the acquisition of all shares in the German company Filtertechnik Jäger GmbH and the Danish company GMV A/S.
-
Knowledge
3/27/2025
Termination Due to Poor Work Performance – How to Act Correctly as an Employer
As an employer, it can be challenging to know how to handle an employee who is not performing as expected and when it is serious enough to justify termination. The so-called LAS reform of 2022, where the term "objective grounds" was replaced with...
-
Read more news and insights?